0001906324-23-000061.txt : 20231201 0001906324-23-000061.hdr.sgml : 20231201 20231201164037 ACCESSION NUMBER: 0001906324-23-000061 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231127 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QuidelOrtho Corp CENTRAL INDEX KEY: 0001906324 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 874496285 FISCAL YEAR END: 0101 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41409 FILM NUMBER: 231460133 BUSINESS ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 552-1100 MAIL ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Coronado Topco, Inc. DATE OF NAME CHANGE: 20220124 8-K 1 qdel-20231127.htm 8-K qdel-20231127
0001906324false00019063242023-11-272023-11-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 27, 2023

QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)

Delaware
001-41409

87-4496285
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

9975 Summers Ridge Road, San Diego, California 92121
(Address of principal executive offices, including zip code)
(858552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director

On November 27, 2023, Stephen H. Wise informed the board of directors (the “Board”) of QuidelOrtho Corporation (the “Company”) of his intent to resign from the Board and as a member of its Nominating and Corporate Governance Committee, effective upon the election of James R. Prutow as a director, which occurred on November 28, 2023 as described below. Mr. Wise’s decision to resign from the Board was due to other professional commitments and was not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Election of Director

On November 28, 2023, the Board elected Mr. Prutow as a director, effective immediately. He qualifies as an “independent director” under the applicable rules of The Nasdaq Stock Market LLC. It is currently anticipated that the Board will appoint Mr. Prutow as a member of the Nominating and Corporate Governance Committee and the Science and Technology Committee.

Mr. Prutow was elected to the Board pursuant to the Principal Stockholders Agreement, dated as of December 22, 2021, by and among the Company, Quidel Corporation, Ortho Clinical Diagnostics Holdings plc and Carlyle Partners VI Cayman Holdings, L.P. (the “Carlyle Stockholder,” and such agreement, the “Principal Stockholders Agreement”). Pursuant to the Principal Stockholders Agreement, among other matters, the Carlyle Stockholder is entitled to designate two directors to the Board so long as it holds at least 12% of the outstanding shares of the Company's common stock. As of November 28, 2023, the Carlyle Stockholder held more than 12% of the outstanding shares and was therefore entitled to designate two directors to the Board. Mr. Prutow is one of two directors designated by the Carlyle Stockholder.

The foregoing description of the Principal Stockholders Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which was filed as Exhibit 10.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023 filed with the U.S. Securities and Exchange Commission on February 23, 2023, which is incorporated herein by reference.

Except as described above, there are no other arrangements or understandings between Mr. Prutow and any other persons pursuant to which he was selected as a director. There are no family relationships between Mr. Prutow and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction that would require disclosure pursuant to Item 404(a) of Regulation S-K.

Severance and Change in Control Agreement

Each of Douglas Bryant, Robert Bujarski, Joseph Busky and Michelle Hodges entered into a Severance and Change in Control Agreement with the Company (the “Severance and CIC Agreement”), which supersedes and replaces any of their respective prior agreements or offer letters entered into with the Company or its affiliates or subsidiaries governing severance and/or change in control. The Severance and CIC Agreement provides for the payment of severance benefits if (1) the executive’s employment with the Company is terminated by the Company without Cause (as defined in the Severance and CIC Agreement) more than thirty days prior to or more than two years following a Change in Control (as defined in the Severance and CIC Agreement) (a “Non-CIC Qualifying Termination”) or (2) the executive’s employment with the Company terminates within two years following or thirty days prior to a Change in Control (a “CIC Qualifying Termination”) for any reason other than the executive’s voluntary resignation (which does not include resignations stemming from a material adverse change in compensation, title, status, overall position, responsibilities, authority, reporting relationship or location of workplace), the executive’s death or permanent disability, or the executive’s termination by the Company for Cause.

The severance benefits under the Severance and CIC Agreement generally consist of a lump sum cash payment equal to two times the sum of (1) the executive’s highest annual base salary with the Company within the three-year period ending on the date of termination, plus (2) an amount equal to the annualized average of all cash bonuses and cash incentive compensation paid to the executive during the two-year period immediately before the date of termination. In addition, the Severance and CIC Agreement provides for: (a) payment of $25,000 to help defray legal, tax and accounting fees, executive outplacement services and other costs associated with transitional matters; (b) continued coverage for two years under our group medical insurance, group dental insurance and group vision insurance programs or equivalent compensation by alternative means, unless and to the extent the executive obtains concurrent coverage through another program, in which case our coverage will be terminated or reduced as applicable; and (c) in the event of a CIC Qualifying Termination (but not, for avoidance of doubt a Non-CIC Qualifying Termination), immediate vesting and exercisability of any and all unvested stock options, restricted stock units and any other equity awards held by the executive, unless previously waived or otherwise expressly agreed to by the executive (with any outstanding performance-based equity awards being deemed earned at the greater of the target level of performance or



actual performance through the date of the Change in Control). Severance benefits are contingent upon the executive executing a customary general release of claims and the executive’s continued compliance, in all material respects, with the terms of the Severance and CIC Agreement.

Werner Kroll did not enter into the Severance and CIC Agreement, and his prior change in control agreement and Amended and Restated Individual Retirement Program, effective as of April 4, 2023, remain in effect.

The foregoing description of the Severance and CIC Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K ("Form 8-K"), which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Form 8-K:

Exhibit NumberDescription of Exhibit
10.1
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 1, 2023
   
QUIDELORTHO CORPORATION
  
By:/s/ Michelle A. Hodges 
Name:Michelle A. Hodges 
Its:Secretary 


EX-10.1 2 ex101formofseveranceandcha.htm EX-10.1 Document
Exhibit 10.1
SEVERANCE AND CHANGE IN CONTROL AGREEMENT
 
This SEVERANCE AND CHANGE IN CONTROL AGREEMENT (this “Agreement”) is dated as of [DATE] and is entered into by and between [EXECUTIVE] (“Executive”) and QuidelOrtho Corporation, a Delaware corporation (the “Company”).
 
Background
 
A.    The Company believes that because of its position in the industry, financial resources and historical operating results, there is a possibility that the Company may become the subject of a Change in Control (as defined below), either now or at some time in the future.
 
B.    The Company further believes that it is in the best interest of the Company and its stockholders to foster Executive’s objectivity in making decisions that may result in Executive’s position being eliminated or otherwise involuntarily terminated and/or with respect to any pending or threatened Change in Control and to assure that the Company will have the continued dedication and availability of Executive, notwithstanding the possibility, threat or occurrence of such a Change in Control and/or possibility or threat of such an involuntary termination of employment. The Company believes that these goals can best be accomplished by alleviating certain of the risks and uncertainties with regard to Executive’s financial and professional security that would be created by an involuntary termination and/or a pending or threatened Change in Control and that inevitably could distract Executive and could impair [his/her] ability to objectively perform [his/her] duties for and on behalf of the Company. Accordingly, the Company believes that it is appropriate and in the best interest of the Company and its stockholders to provide to Executive compensation arrangements upon an involuntary termination and/or a Change in Control that reduce Executive’s financial risks and uncertainties and that are reasonably competitive with those of other peer corporations.

C.    This Agreement shall supersede and replace any prior agreements or offer letters governing severance and/or change in control entered into by and between the Company or its affiliates or subsidiaries, including but not limited to Quidel Corporation, Ortho Clinical Diagnostics Holdings Limited (fka Ortho Clinical Diagnostics Holdings plc), Ortho-Clinical Diagnostics, Inc. and Ortho-Clinical Diagnostics Bermuda Co. Ltd., and Executive, and any such prior agreements or offer letters, in each case to the extent covering the subject matter hereof, shall be terminated automatically upon execution of this Agreement, without any further action by the parties.

D.    With these and other considerations in mind, the Compensation Committee of the Company’s Board of Directors has authorized the Company to enter into this Agreement with the Executive to provide the protections set forth herein for Executive’s financial security in connection with an involuntary termination and/or a Change in Control.
 
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration the receipt of which is hereby acknowledged, it is hereby agreed as follows:
 
Agreement
 
1.    Term of Agreement. The term of this Agreement shall commence as of the date first set forth above, or if later, the commencement of work by Executive with the Company or one of its affiliates (the applicable date, the “Effective Date”) and, subject to the provisions of Section 3, shall continue until (and thereupon automatically terminate) the earlier of (i) the second anniversary of the Effective Date (as the same may be extended pursuant to the automatic extension provision set forth below in this paragraph) and (ii) the date of Executive’s termination of employment with the Company for any reason (the “Termination Date”). On the second anniversary of the Effective Date and each annual anniversary of such date thereafter (in either case, provided Executive’s employment has not been terminated prior thereto), the term of this Agreement shall automatically be extended for one additional year unless the Company gives written notice of non-renewal to Executive at least 12 months prior to the automatic extension date. No termination of this Agreement shall limit, alter or otherwise affect Executive’s rights



hereunder with respect to a Non-CIC Qualifying Termination (as defined below) or a Change in Control which has occurred on or prior to such Termination Date, including without limitation Executive’s right to receive the various benefits provided hereunder.

2.    Purpose of Agreement. The purpose of this Agreement is to provide that, in the event of a Non-CIC Qualifying Termination or Change in Control and accompanying CIC Qualifying Termination (as defined below), Executive may become entitled to receive certain benefits, as described herein. As used in this Agreement, the term “Change in Control” shall have the meaning set forth in the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) (as the same may be amended from time to time or in any successor equity incentive plan).

3.    Non-CIC Qualifying Termination. In the event Executive’s employment with the Company is terminated without Cause during the term of this Agreement outside of the Protection Period (“Cause” and “Protection Period” each as defined in Section 4 below), such termination shall be conclusively considered a “Non-CIC Qualifying Termination.” In the event of a Non-CIC Qualifying Termination, Sections 5 through 12 of this Agreement shall become applicable to Executive, to the extent applicable to such termination.
 
4.    Change in Control and CIC Qualifying Termination. In the event of a Change in Control, Sections 5 through 12 of this Agreement shall become applicable to Executive, to the extent applicable to such termination. These Sections shall continue to remain applicable until the second anniversary of the date upon which the Change in Control occurs and this Agreement may not expire or be terminated during such period unless, during such period, Executive terminates employment for a reason other than a CIC Qualifying Termination, in which case this Agreement shall terminate upon such termination of employment. If, within two (2) years following or thirty (30) days prior to a Change in Control (the “Protection Period”), Executive’s employment with the Company is terminated, such termination shall be conclusively considered a “CIC Qualifying Termination” unless:
 
(a)    Executive voluntarily terminates [his/her] employment with the Company. Executive, however, shall not be considered to have voluntarily terminated [his/her] employment with the Company if, within the Protection Period, Executive’s base salary is reduced in any material respect, or Executive’s authority or duties are materially adversely changed, and subsequent to such reduction or change Executive elects to terminate [his/her] employment with the Company within sixty (60) days following such reduction or change after having given the Company at least thirty (30) days’ notice of the same and a reasonable opportunity to cure during such 30-day notice period. For such purposes, Executive’s authority or duties shall conclusively be considered to have been “materially adversely changed” if, without Executive’s express and voluntary written consent, during the Protection Period, there is any substantial diminution or adverse modification in Executive’s title, status, overall position, responsibilities, reporting relationship, or if, without Executive’s express and voluntary written consent, Executive’s job location is transferred to a site more than twenty-five (25) miles away from [his/her] place of employment as of the date immediately prior to the beginning of the Protection Period. In this regard as well, Executive’s authority and duties shall conclusively be considered to have been “materially adversely changed” if, without Executive’s express and voluntary written consent, during the Protection Period, Executive no longer holds the same title or no longer has the same authority and responsibilities or no longer has the same reporting responsibilities, in each case with respect and as to a publicly held parent company which is not controlled by another entity or person. For avoidance of doubt, any promotion that has the effect of changing Executive’s title, status, authority, overall position, responsibilities, and/or reporting relationship shall not be deemed to constitute a “material adverse change” in Executive’s authority or duties for purposes of this Agreement.
 
(b)    The termination is on account of Executive’s death or Permanent Disability. For such purposes, “Permanent Disability” shall mean a physical or mental incapacity as a result of which Executive becomes unable to continue the performance of [his/her] responsibilities for the Company and its affiliated companies and which, at least
2



three (3) consecutive months after its commencement, is determined to be a “permanent and total disability” as defined in Section 22(e) of the Internal Revenue Code of 1986, as amended (the “Code”) (or any successor provision) by a physician agreed to by the Company and Executive, or in the event of Executive’s inability to designate a physician, Executive’s legal representative. In the absence of agreement between the Company and Executive, each party shall nominate a qualified physician and the two physicians so nominated shall select a third physician who shall make the determination as to Permanent Disability.

(c)    Executive’s employment with the Company is involuntarily terminated for Cause. For this purpose, “Cause” shall be limited to only three types of events:
 
(1)    the willful and deliberate refusal or failure of Executive to comply with a lawful, written instruction of the Board of Directors, including material Company policies and agreements, which refusal or failure is not remedied by Executive within a reasonable period of time after [his/her] receipt of written notice from the Company identifying the refusal or failure, so long as the instruction is consistent with the scope and responsibilities of Executive’s position prior to the Change in Control;
 
(2)    a willful and deliberate act or acts of personal dishonesty by Executive which result in or are reasonably likely to result in material harm to the Company; or
 
(3)    Executive’s conviction of or plea of nolo contendere to any felony involving an act of moral turpitude.

For purposes hereof, no act, or failure to act, on the Executive’s part shall be deemed “willful” if the Executive reasonably believed such act(s) or omission(s) were in the best interests of the Company.

5.    Severance Payment. If Executive’s employment is terminated as a result of a Non-CIC Qualifying Termination or a CIC Qualifying Termination (such a termination, whether a Non-CIC Qualifying Termination or a CIC Qualifying Termination, shall be referred to herein as an “Involuntary Termination”), contingent upon Executive executing a customary general release of claims in favor of the Company and such release becoming effective and irrevocable in accordance with its terms, and Executive’s continued compliance, in all material respects, with the terms of this Agreement, the Company shall pay Executive within thirty (30) days after the Involuntary Termination and delivery of such release and the expiration of any revocation period, a cash lump sum equal to two (2) times the Executive’s Compensation (the “Severance Payment”).
 
(a)    For purposes of this Agreement, Executive’s “Compensation” shall equal the sum of (i) Executive’s highest annual base salary with the Company within the three year period ending on the date of Executive’s Involuntary Termination, plus (ii) a Bonus Increment. The “Bonus Increment” shall equal the annualized average of all cash bonuses and cash incentive compensation payments paid to Executive during the two (2) year period immediately before the date of Executive’s Involuntary Termination under all of the Company’s bonus and incentive compensation plans or arrangements.

(b)    The Severance Payment hereunder is in lieu of any severance payment that Executive might otherwise be entitled to from the Company in the event of an Involuntary Termination and/or a Change in Control under the Company’s applicable severance pay policies, if any, or under any other oral or written agreement.
 
(c)    Notwithstanding any provision of this Agreement to the contrary, if, at the time of Executive’s termination of employment with the Company, Executive is a “specified employee” as defined in Section 409A of the Code, and one or more of the payments or benefits received or to be received by Executive pursuant to this Agreement
3



(or any portion thereof) would become subject to the additional tax under Section 409A(a)(1)(B) of the Code or any other taxes or penalties imposed under Section 409A of the Code (collectively, the “Section 409A Taxes”) if provided at the time otherwise required under this Agreement, no such payment or benefit will be provided under this Agreement until the earlier of (i) the date which is six (6) months after Executive’s “separation from service” or (ii) the date of Executive’s death, or such shorter period that, as determined by the Company, is sufficient to avoid the imposition of Section 409A Taxes. The provisions of this Section 5(c) shall only apply to the minimum extent required to avoid Executive’s incurrence of any Section 409A Taxes. In addition, if any provision of this Agreement would cause Executive to incur any penalty tax or interest under Section 409A of the Code or any regulations or Treasury guidance promulgated thereunder, the Company may reform such provision of this Section 5(c) to maintain to the maximum extent practicable the original intent of the applicable provision without violating the provisions of Section 409A of the Code or such regulations or Treasury guidance promulgated thereunder.

(d)    The Company may withhold from any amounts payable under this Agreement such federal, state or local taxes as shall be required to be withheld pursuant to any applicable law or regulation.

(e)    Notwithstanding the foregoing, any severance benefits payable under this Section 5 shall be reduced by any severance or termination benefits payable under any federal, state, local or non-U.S. jurisdictional law, but not less than zero.
 
6.    Additional Benefits.
 
(a)    In the event of a CIC Qualifying Termination (but not, for avoidance of doubt, a Non-CIC Qualifying Termination), any and all unvested stock options, restricted stock units or any other Awards as such term is defined under the 2018 Plan (as the same may be amended from time to time or in any successor equity incentive plan) held by Executive shall immediately become fully vested and, if applicable, exercisable and any and all restrictions on Executive’s restricted stock or other Awards shall immediately and automatically lapse (except as otherwise expressly agreed to, in writing, by both parties, whether prior to, concurrent with, or after the execution of this Agreement). For any Awards that are subject to performance-based vesting criteria for which the performance period has not been completed and certified, if applicable, prior to the Change in Control, such performance-based criteria will be deemed earned at the greater of the target level of performance or actual performance through the date of the Change in Control.
 
(b)    In the event of an Involuntary Termination, Executive shall be entitled to continue to participate in the following executive benefit programs which had been made available to Executive (including [his/her] family) before the Involuntary Termination: group medical insurance, group dental insurance, and group vision insurance. These programs shall be continued at no cost to Executive, except (i) with respect to monthly payments Executive would pay for coverage under such programs if Executive was an active employee of the Company and (ii) to the extent that tax rules require the inclusion of the value of such benefits in Executive’s income. The programs shall be continued in the same way and at the same level as immediately prior to the Involuntary Termination. The programs shall continue for Executive’s benefit for two (2) years after the date of the Involuntary Termination; provided, however, that (1) Executive’s participation in each of such programs shall be earlier terminated or reduced, as applicable, if and to the extent Executive receives benefits as a result of concurrent coverage through another program, whether by virtue of a new employer or otherwise and (2) in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and Affordable Care Act or Section 105(h) of the Code, or otherwise violate or not be covered under the terms of the applicable benefit plans, Executive and the Company
4



agree to work together in good faith to restructure the foregoing benefit, including the Company providing equivalent compensation by alternative means to Executive.

(c)    In the event of an Involuntary Termination, Executive shall be entitled to receive from the Company, upon such Involuntary Termination, the sum of $25,000 to help defray legal fees, tax and accounting fees, executive outplacement services, and other costs associated with transitional matters.
 
7.    Limitation on Payments. Notwithstanding anything to the contrary herein, in the event that the sum aggregate present value of (i) the Severance Payment payable under Section 5 hereof, (ii) any and all additional amounts or benefits which may be paid or conferred to or on behalf of Executive in accordance with Section 6 hereof, and (iii) any and all other amounts or benefits paid or conferred to or on behalf of Executive that would constitute a “parachute payment” (“parachute payment” as used in this Agreement shall be defined in accordance with Section 280G(b)(2), or any successor thereto, of the Code), the payments under this Agreement shall be reduced (by the minimum possible amounts) until no amount payable to Executive under this Agreement constitutes a parachute payment; provided, however, that no such reduction under this Section 7 shall be made if the net after-tax payment (after taking into account, Federal, state, local or other income and excise taxes) to which Executive would otherwise be entitled without such reduction would be greater than the net after-tax payment (after taking into account Federal, state, local or other income and excise taxes) to Executive resulting from the receipt of such payments with such reduction. If, as a result of subsequent events or conditions (including a subsequent payment or absence of a subsequent payment under this Agreement), it is determined that payments hereunder have been reduced by more than the minimum amount required under this Section 7, then an additional payment shall be promptly made to Executive in an amount and to the extent equal to the excess reduction. All determinations required to be made under this Section 7, including whether a payment would result in a parachute payment and the assumptions to be utilized in arriving at such determination, shall be made and approved within fifteen (15) days after the Involuntary Termination by both (1) accountants selected by the Company and (2) Executive’s designated financial or legal advisor.
 
8.    Non-Disparagement; Proprietary Information; Cooperation.

(a)    Both during employment and for a period of two (2) years following the Involuntary Termination (the “Restricted Period”), Executive shall not make, publicly or privately, any statements (orally or in written form) that disparage, or could otherwise cause harm to, the business or reputation of the Company, and/or any officer, director or employee of the Company.

(b)    During the Restricted Period, Executive agrees not to voluntarily aid, advise or otherwise assist any competitor of the Company, stockholder of the Company, litigant or potential litigant against the Company in asserting, prosecuting, or defending any claim, or making any similar demands, against the Company, and further, Executive shall promptly notify the Company in writing if Executive is approached by any party, other than government entities, concerning any such matters.

(c)    Executive acknowledges access to and receipt of confidential business and proprietary information regarding the Company. Executive remains subject to the terms of the [Agreement re Confidential Information, Inventions, Non-Solicitation and Non-Competition1 / Agreement re Confidential Information, Inventions, Non-Solicitation and Conflicts of Interest2 / Non-Competition, Non-Solicitation, Secrecy & Intellectual Property Agreement3] (as the same may be amended from time to time or in any successor agreement), which are incorporated by reference herein.

1 QuidelOrtho agreement
2 Legacy Quidel agreement
3 Legacy Ortho agreement
5



(d)    With regard to this Section 8, Executive acknowledges that the provisions herein are reasonable in both scope and duration and necessary to protect the business of the Company or its successor.
(e)    Executive acknowledges and agrees that the restrictive covenants set forth in this Section 8 are intended to be in addition to any other restrictive covenants that may be set forth in a separate written agreement between the Executive and the Company.
(f)    Notwithstanding the foregoing, nothing in this Agreement shall prohibit Executive from (i) making truthful statements or disclosures that are required by applicable law, regulation or legal process; (ii) requesting or receiving confidential legal advice; (iii) cooperating, participating or filing charges with any federal, state or local government agency enforcing discrimination laws; or (iv) reporting suspected violations of law. In addition, nothing herein shall prevent Executive from discussing or disclosing information regarding unlawful acts in the workplace, such as harassment, discrimination or any other conduct that Executive has reason to believe is unlawful.
9.    No Right to Continued Employment. Unless otherwise expressly set forth in a separate written employment agreement between Executive and the Company, the employment of Executive is expressly at-will, and Executive or the Company may terminate Executive’s employment with the Company at any time and for any reason, with or without cause, provided that if such termination constitutes an Involuntary Termination under this Agreement, the provisions of this Agreement shall govern the payment of the Severance Payment and certain other benefits as provided herein.
 
10.    Non-Exclusivity of Rights. Subject to Section 6(b) hereof, nothing in this Agreement shall prevent or limit Executive’s continuing or future participation in any benefit, bonus, incentive or other plan or program provided by the Company and for which Executive may qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under any stock option grant, restricted stock unit grant or other agreements with the Company. Except as otherwise provided in Section 6(b) hereof, amounts that are vested benefits or that Executive is otherwise entitled to receive under any plan or program of the Company at or subsequent to the date of any Involuntary Termination shall be payable in accordance with such plan or program.
 
11.    Full Settlement. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counter-claim, recoupment, defense or other claim, right, or action that the Company may have against Executive or others; provided that such payments shall be subject to the provisions of the Company’s Amended and Restated Clawback Policy, any other clawback policy of the Company and any applicable legislation (e.g., Dodd-Frank), in each case as may be amended from time to time. In no event shall Executive be obligated to seek other employment or to take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement. The Company agrees to pay, to the full extent permitted by law, all legal fees and expenses that Executive may reasonably incur as a result of Executive’s successful collection efforts to receive amounts payable hereunder, or as a result of any contest (regardless of the outcome thereof) by the Company or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by Executive about the amount of any payment pursuant to this Section).

12.    Successors.
 
(a)    This Agreement is personal to Executive, and without the prior written consent of the Company shall not be assignable by Executive other than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive’s legal representatives.
 
6



(b)    The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company.

(c)    Unless the context otherwise requires, all references to the Company in this Agreement shall include its controlled subsidiaries.
 
13.    Governing Law. This Agreement is made and entered into in the State of California, and the internal laws of California shall govern its validity and interpretation in the performance by the parties hereto of their respective duties and obligations hereunder.
 
14.    Modifications. This Agreement may be amended or modified only by an instrument in writing executed by both of the parties hereto.
 
15.    Dispute Resolution.

(a)    Any controversy or dispute between the parties involving the construction, interpretation, application or performance of the terms, covenants, or conditions of this Agreement or in any way arising under this Agreement shall be resolved on an individual basis through final and binding arbitration before a single arbitrator in San Diego, California, or another location mutually agreed upon by the parties, pursuant to the JAMS Rules in effect when the dispute is submitted to arbitration (the applicable rules can be found at the JAMS website (www.jamsadr.com)). This agreement to arbitrate does not apply in the event a government agency brings a claim on Executive’s behalf. Notwithstanding the provision in this Agreement with respect to applicable substantive law, any arbitration conducted pursuant to the terms of this Agreement shall be governed by the Federal Arbitration Act (9 U.S.C., Secs. 1-16). This Agreement shall be admissible in any proceeding to enforce its terms. Notwithstanding the mandatory arbitration procedures set forth in this Section 15, any party hereto may seek emergency, temporary or preliminary injunctive relief from a court of competent jurisdiction to seek enforcement of this Section 15 or in aid of arbitration or pending final adjudication of a claim in arbitration where the arbitration award may be rendered ineffectual without such relief. The parties hereto intend this arbitration provision to be valid, enforceable, irrevocable and construed as broadly as possible. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; (ii) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award; and (iii) be authorized to award any or all remedies that the parties would be entitled to seek in a court of law.
(b)    BY SIGNING THIS AGREEMENT, THE PARTIES HERETO GIVE UP ALL RIGHTS TO A JURY TRIAL AND GIVE UP THE RIGHT TO PROCEED ON A CLASS, COLLECTIVE OR REPRESENTATIVE ACTION BASIS AS TO CLAIMS COVERED UNDER THIS AGREEMENT (“CLASS ACTION WAIVER”). The parties hereto agree that arbitration of any claims pursuant to this Agreement will proceed solely on an individual basis and that any claims by a party in arbitration may not be joined or combined with the claims of another party, such as a class action, or on the basis that one party stands as a representative for a group of individuals or entities, except as otherwise set forth herein. Such a class, collective, representative or joint action is prohibited by this Agreement unless both parties expressly agree to such a collective or joint action in writing. In any case in which (A) the dispute is filed as a class, collective or representative action and (B) there is a final judicial determination that the class, collective and/or representative action must be litigated in a court of competent jurisdiction, the portion of the Class Action Waiver that is enforceable shall be enforced in arbitration. Notwithstanding any other clause contained in this Agreement or the JAMS Rules, any claim that all or part of this Class Action Waiver is unenforceable, unconscionable, void or voidable may be determined only by a court of competent jurisdiction and not by an arbitrator. All other disputes with respect to whether this Agreement is unenforceable, unconscionable, applicable, valid, void or
7



voidable shall be determined exclusively by an arbitrator, and not by any court. Any claims, whether related or unrelated to any class, collective, representative or joint claim, that can validly be required to proceed on an individual basis shall remain subject to arbitration under the terms of this Agreement. Any claim that is required to proceed in a court of competent jurisdiction pursuant to the terms of this Section shall be stayed pending arbitration of any other claims that may proceed in arbitration on an individual basis, and shall be required to return to arbitration in the event the lawsuit does not proceed on a class, collective, consolidated or representative basis. In no event shall any class, collective, consolidated or representative proceeding brought on behalf of others be permitted to proceed in arbitration.

(c)    The Company shall bear the costs of the arbitration of any dispute arising out of this Agreement. Except as otherwise agreed to in this Agreement, the parties hereto acknowledge and agree that in connection with any such arbitration, each party will pay all of its own costs and expenses (unless otherwise stated herein or if statutorily permitted), including its own legal fees and expenses; provided that the arbitrator shall have the authority to award the prevailing party its reasonable legal fees, costs and expenses incurred in such arbitration.

(d)    The arbitrator shall have the authority to decide jurisdictional and arbitrability disputes, including disputes over the formation, existence, validity, interpretation or scope of the agreement under which arbitration is sought, and who are proper parties to the arbitration. However, notwithstanding the preceding sentence, the arbitrator shall have no authority to decide disputes relating to the enforceability of any of the portions of this Agreement requiring claims to be arbitrated on an individual basis, or that claims not be brought on a class, collective, consolidated or representative basis, including any claim that all or part of this Class Action Waiver is unenforceable, unconscionable, void or voidable, and such questions shall be reserved for a court of competent jurisdiction.
 
16.    Notices. Any notice or communications required or permitted to be given to the parties hereto shall be delivered personally or be sent by United States registered or certified mail, postage prepaid and return receipt requested, and addressed or delivered as follows, or at such other addresses the party addressed may have substituted by notice pursuant to this Section:
 
QuidelOrtho Corporation [EXECUTIVE]
9975 Summers Ridge Road [ADDRESS]
San Diego, CA 92121 [ADDRESS]
Attn: President & CEO4  
 
17.    Captions. The captions of this Agreement are inserted for convenience and do not constitute a part hereof.
 
18.    Severability. In case any one or more of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein and there shall be deemed substituted for such invalid, illegal or unenforceable provision such other provision as will most nearly accomplish the intent of the parties to the extent permitted by the applicable law. In case this Agreement, or any one or more the provisions hereof, shall be held to be invalid, illegal or unenforceable within any governmental jurisdiction or subdivision thereof, this Agreement or any such provision thereof shall not as a consequence thereof be deemed to be invalid, illegal or unenforceable in any other governmental jurisdiction or subdivision thereof.
4 If Executive is the President & CEO, notices should be directed to the Company’s General Counsel.
8



 
19.    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall together constitute one in the same Agreement.
 


[Remainder of page left blank intentionally, signatures on following page]
 
9



IN WITNESS HEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first written above.
 

QUIDELORTHO CORPORATION, a Delaware corporation



By:    
    Printed Name:
    Title:
    



EXECUTIVE        



By:    
[EXECUTIVE]

[Signature Page to Severance and Change in Control Agreement for [EXECUTIVE]]
EX-101.SCH 3 qdel-20231127.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 qdel-20231127_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 qdel-20231127_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Address Type [Domain] Address Type [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 qdel-20231127_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information Document
Nov. 27, 2023
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 27, 2023
Entity Incorporation, State or Country Code DE
Entity File Number 001-41409
Entity Tax Identification Number 87-4496285
Entity Address, Address Line One 9975 Summers Ridge Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 552-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol QDEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001906324
Amendment Flag false
Entity Registrant Name QUIDELORTHO CORP
XML 8 qdel-20231127_htm.xml IDEA: XBRL DOCUMENT 0001906324 2023-11-27 2023-11-27 0001906324 false 8-K 2023-11-27 QUIDELORTHO CORP DE 001-41409 87-4496285 9975 Summers Ridge Road San Diego CA 92121 858 552-1100 false false false false Common Stock, $0.001 Par Value QDEL NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.quidel.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports qdel-20231127.htm qdel-20231127.xsd qdel-20231127_def.xml qdel-20231127_lab.xml qdel-20231127_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "qdel-20231127.htm": { "nsprefix": "qdel", "nsuri": "http://www.quidel.com/20231127", "dts": { "inline": { "local": [ "qdel-20231127.htm" ] }, "schema": { "local": [ "qdel-20231127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "qdel-20231127_def.xml" ] }, "labelLink": { "local": [ "qdel-20231127_lab.xml" ] }, "presentationLink": { "local": [ "qdel-20231127_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.quidel.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "qdel-20231127.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "qdel-20231127.htm", "first": true, "unique": true } } }, "tag": { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001906324-23-000061-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001906324-23-000061-xbrl.zip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end